Investors back Infinity stock offer on new early data, surging PI3K interest
This article was originally published in Scrip
Executive Summary
With only early-stage data in hand for its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma IPI-145, Infinity Pharmaceuticals' recent $150 million common stock offering and response to preliminary Phase I results in hematological malignancies seems to reflect enthusiasm for PI3K inhibitors as a class - although the company says its findings so far show that it may have a class-leading therapeutic candidate.